David McKinley actually said...

Policies like referencing pricing and government price-settings will effectively turn our biopharma industry to a risk-averse, think-inside-...

But pursuing this highly partisan H.R. 3 is just an example of overreach, unfortunate overreach, that occurs too often in Washington, and it...

I want to respond to my good friend, Representative Castor, with regard--she brought up the VA.

We need a robust biopharma industry, and I think everyone agrees to that, investing in rare diseases.